RATIONALE: Aspirin challenge and desensitization remains the gold standard in diagnosis and treatment of patients with aspirin-exacerbated respiratory disease (AERD), but the protocols can be time and resource intensive. The objective of this study is to provide evidence that oral aspirin challenge and desensitization can be safely performed in an outpatient setting in one day. METHODS: Forty-four patients with confirmed diagnosis of AERD, stable asthma and baseline FEV1 > _70% of predicted completed an oral aspirin challenge and desensitization protocol. The starting dose was 40.5mg with escalating doses of aspirin (81, 162.5, 325mg) at 90-minute intervals until symptoms were provoked. Desensitization was defined as tolerating a repeated administration of the provocative dose and at least one subsequent aspirin dose, bringing total aspirin ingested during the in-clinic desensitization to > _325mg. RESULTS: Ninety-three percent of patients completed the challenge and desensitization in one day, with an average protocol completion time of 9 hours and 29 minutes. Two patients (4.6%) chose to complete the protocol over two days. One patient (2.3%) was discontinued from the protocol due to on-going abdominal discomfort and diarrhea. No patient required epinephrine, emergency department visit or hospitalization. CONCLUSIONS: Patients with AERD on a stable asthma regimen and with a baseline FEV1> _70% can be safely desensitized to aspirin using a 90-minute dose escalation protocol, starting at a dose of 40.5mg, and defining desensitization as tolerance of the repeated provocation dose and at least one subsequent aspirin dose, bringing total cumulative daily dose to > _325mg. This protocol can routinely be completed in one day. (2016)(2017)(2018). Patients were included if they had 20 weeks of continuous data from electronic medication monitors (EMMs) that passively collected time and date of actuations. The onboarding period (week 1) was excluded from analysis. Weekly rescue use and controller adherence was assessed for weeks 2-20. Adherence was calculated as the total number of controller actuations divided by the number prescribed (%). Mean weekly rescue use and adherence was compared for the six age groups (8-11; 12-14; 15-17; 18-21; 22-25; and 26-29) using one-way ANOVA. RESULTS: Controller adherence and rescue use statistically differed by age group (P < 0.01), with the greatest mean (standard deviation) adherence (38% [29]) and lowest rescue use (2.1 actuations/week [3.4]) for ages 8-11 years. Mean weekly controller adherence declined in adolescent and young adult groups, with lowest estimates for ages 18-21 years (28% [26]), and then gradually rose in for ages 22-25 and 26-29 years. Rescue use steadily increased with age, reaching 4.7 actuations/week (9.9) for patients aged 26-29 years. CONCLUSIONS: Highest adherence and lowest rescue use was observed in those 8-11 years, and controller adherence declined with increasing age, possibly reflecting the switch from parental supervision of medication administration to independent decision-making. The decline in controller adherence may signal worsening asthma control during times of transition and demonstrates potential need for age-specific interventions.
. Patients were included if they had 20 weeks of continuous data from electronic medication monitors (EMMs) that passively collected time and date of actuations. The onboarding period (week 1) was excluded from analysis. Weekly rescue use and controller adherence was assessed for weeks 2-20. Adherence was calculated as the total number of controller actuations divided by the number prescribed (%). Mean weekly rescue use and adherence was compared for the six age groups (8-11; 12-14; 15-17; 18-21; 22-25; and 26-29) METHODS: Five patients with severe persistent eosinophilic asthma, who were to begin Reslizumab treatment, had levels of nitric oxide monitored prior to the first treatment, and then monthly after each infusion. RESULTS: Five patients with eosinophilia ranging from 400 to 1300/mL with severe persistent asthma began treatment with Reslizumab, an intravenously administered monoclonal antibody against interleukin-5. Prior to beginning treatment, their FeNO levels ranged from 62 to 186ppb. Within 6 months, the FeNO of four of the patients came down dramatically 
